MK-677 (Ibutamoren)
Oral non-peptide GH secretagogue. Mimics ghrelin to stimulate GH release. Long half-life allows once-daily oral dosing. Not a SARM despite common miscategorisation.
Overview
Oral non-peptide GH secretagogue. Mimics ghrelin to stimulate GH release. Long half-life allows once-daily oral dosing. Not a SARM despite common miscategorisation.
Elevates GH and IGF-1 levels (sustained), can elevate fasting glucose and worsen insulin sensitivity (significant concern), increases appetite markedly, may cause water retention, can elevate prolactin mildly, may worsen lipids through insulin resistance
Compound Guide
Structure: Non-peptide ghrelin mimetic — small molecule that binds the ghrelin (GHSR) receptor. Oral bioavailability distinguishes it from injectable GH peptides.
Dosage:
- Standard: 10-25mg/day oral
- Conservative (minimise glucose impact): 10-15mg/day
- Enhanced: 25mg/day (more GH release but worse glucose/insulin)
Administration:
- Oral capsule or liquid, once daily
- Take before bed — GH release during sleep, and hunger side effect is slept through
- Can be taken with or without food
Key Notes:
- Main advantage: oral dosing (no injections), long half-life (once daily), relatively inexpensive
- Main disadvantage: SIGNIFICANT impact on blood glucose and insulin sensitivity — this is the major concern
- Increased appetite can be extreme — counterproductive for cutting (some users gain unwanted fat)
- Fasting glucose and HbA1c can rise substantially, especially at 25mg/day
- Consider adding Metformin or Berberine to mitigate glucose impact
- Elevates prolactin mildly in some users — monitor if symptoms arise
- Water retention and bloating are common (similar to exogenous GH)
- Monitor: fasting glucose, HbA1c, IGF-1, fasting insulin, prolactin, lipid panel
- Not suppressive to HPTA — can be run year-round (but glucose impact may limit duration)
How far fasting glucose typically moves in the first four weeks, and when to discontinue: How much does MK-677 raise blood sugar and when to stop.
Usage History
Pairs With
How MK-677 (Ibutamoren) behaves when it is run alongside other compounds.
Commonly stacked with
Used to offset
Stacks the risk
Marker Interactions
Compare With
MK-677 (Ibutamoren) vs Ipamorelin
MK-677 vs Ipamorelin: GH secretagogue comparison for bodybuilders
MK-677 (Ibutamoren) vs Growth Hormone
MK-677 vs Growth Hormone: oral secretagogue vs injectable GH
MK-677 (Ibutamoren) vs CJC-1295 no DAC (mod-GRF)
CJC-1295 No-DAC vs MK-677: Pulsatile vs Continuous GH Stimulation
MK-677 (Ibutamoren) vs Tesamorelin
Tesamorelin vs MK-677: Glucose-Neutral Phase 3 Evidence vs Cheap Oral Glucose Cost
MK-677 (Ibutamoren) vs MOTS-C
MOTS-C vs MK-677: opposite effects on insulin sensitivity
MK-677 (Ibutamoren) vs IGF-1 LR3
IGF-1 LR3 vs MK-677: direct injection vs the GH-axis route
Frequently Asked Questions
Related Articles
Why Your HRV Is Low on TRT (Normal HRV by Age for Men)
Is an HRV of 25 low on TRT? Normal RMSSD by age for men, why wearables disagree, what testosterone, tren, clen and T3 do, and when low HRV matters.
Will Apitegromab (Isembyld) Build Muscle in Healthy Lifters?
Isembyld is the first approved myostatin blocker. No trial has ever measured muscle growth in a healthy adult, and the fracture signal is on the label.
When Will Orforglipron Be Available in Australia? (TGA Update)
Orforglipron (Foundayo) is not TGA approved yet; the Wegovy Pill is. Realistic Australian timeline, trial results, muscle loss and the bloodwork to run.
Is Imeglimin Better Than Metformin for Lifters?
Imeglimin (Twymeeg) is pitched as metformin plus MOTS-c plus NAD+. Here is what the trials show, what they don't, and the labs to run.
Quick Reference
Category
GH
Half-Life
24 hours
Detection Time
N/A